Clinical Trial Update: A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating SYH2053 as monotherapy for non-familial hypercholesterolemia or mixed hyperlipidemia in Chinese participants; recruitment is o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Hyperlipidemia Mixed

Drugs mentioned

• SYH2053

Snippet

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Conditions: Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | Status: RECRUITING